Molecular Health urges efforts in Asia for market entry and product distribution
August 23, 2017Molecular Health, a pioneer in data and analytics-driven precision medicine from Heidelberg, Germany, seeks to expand its efforts to establish collaborations in Asia and the precision-medicine scene there.
In cooperation with its strategic partners, which include some of the world’s best laboratories, universities, and genetic facilities, Molecular Health plans to bring its technology (Dataome) to a region of the world that has started to take considerable steps towards genome sequencing and custom-tailored cancer treatments for individual patients.
The ultimate goal is improving patient care. “Strategic partnerships are a critical component of the design of our company, and our market partners enable us to efficiently bring our products to market,” says Friedrich von Bohlen und Halbach, Chief Executive Officer, speaking of Molecular Health Guide (MH Guide).
This is a treatment decision-support tool in oncology for physicians, hospitals and diagnostic laboratories and is one of the company’s major products. The MH Guide software is registered as an in-vitro diagnostic medical device (IVD) in Europe and is CE-compliant with European regulations. MH Guide includes all of the steps of the clinical genomics workflow in oncology, from raw sequencing data to generating an interactive, editable medical report. It is the first product of its kind in Germany to be reimbursed by public health insurance.
In the future, targeted approaches in oncological therapy will play an important role in treating patients. As tumors are genetically characterized, patient groups most likely to benefit from targeted therapy approaches can be identified prior to treatment.
Molecular Health will be demonstrating its latest product developments at the Precision Medicine & Big Data Congress Asia in Seoul, South Korea, on August 22-23, 2017
